165 related articles for article (PubMed ID: 38334832)
21. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
[TBL] [Abstract][Full Text] [Related]
22. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
23. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
[TBL] [Abstract][Full Text] [Related]
24. Impact of Structural Changes on Multifocal Electroretinography in Patients With Use of Hydroxychloroquine.
Borrelli E; Battista M; Cascavilla ML; Viganò C; Borghesan F; Nicolini N; Clemente L; Sacconi R; Barresi C; Marchese A; Miserocchi E; Modorati G; Bandello F; Querques G
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):28. PubMed ID: 34581725
[TBL] [Abstract][Full Text] [Related]
25. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Mavrikakis I; Sfikakis PP; Mavrikakis E; Rougas K; Nikolaou A; Kostopoulos C; Mavrikakis M
Ophthalmology; 2003 Jul; 110(7):1321-6. PubMed ID: 12867385
[TBL] [Abstract][Full Text] [Related]
26. En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy.
Ahn SJ; Joung J; Lee BR
Am J Ophthalmol; 2019 Mar; 199():71-81. PubMed ID: 30448463
[TBL] [Abstract][Full Text] [Related]
27. Macula pigment optical densitometry changes in hydroxychloroquine use.
Kabataş N; Özateş S; Avarisli NA; Kakil SB; Özişler C
Cutan Ocul Toxicol; 2021 Jun; 40(2):115-118. PubMed ID: 33757380
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Penn SK; Kao AH; Schott LL; Elliott JR; Toledo FG; Kuller L; Manzi S; Wasko MC
J Rheumatol; 2010 Jun; 37(6):1136-42. PubMed ID: 20436082
[TBL] [Abstract][Full Text] [Related]
29. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
Carmichael SJ; Day RO; Tett SE
Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
[TBL] [Abstract][Full Text] [Related]
30. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
Lang MG; Vinagre CG; Bonfa E; Freitas FR; Pasoto SG; Brito TS; Seguro LP; Maranhão RC; Borba EF
Lupus; 2022 May; 31(6):659-665. PubMed ID: 35332823
[TBL] [Abstract][Full Text] [Related]
31. Value of Microperimetry in Detecting Early Retinal Toxicity of Hydroxychloroquine in Children with Juvenile Systemic Lupus Erythematosus.
Youssef MM; El-Fayoumi D; Sidky MK; Hegazy AI; Marzouk H; Eltanamly RM
Ophthalmologica; 2017; 237(3):180-184. PubMed ID: 28297699
[TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Retromode Imaging for Use in Hydroxychloroquine Retinopathy.
Ahn SJ; Lee SU; Lee SH; Lee BR
Am J Ophthalmol; 2018 Dec; 196():44-52. PubMed ID: 30118686
[TBL] [Abstract][Full Text] [Related]
34. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography.
Turgut B; Turkcuoglu P; Serdar Koca S; Aydemir O
Clin Rheumatol; 2009 May; 28(5):607-9. PubMed ID: 19221829
[TBL] [Abstract][Full Text] [Related]
35. Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients.
Ahn SJ; Joung J; Lim HW; Lee BR
Am J Ophthalmol; 2017 Dec; 184():11-18. PubMed ID: 28964805
[TBL] [Abstract][Full Text] [Related]
36. The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus.
Pan M; Jin R; Dai Y; Gao B; Liu Y; Peng X; Qiao J; Shuai Z
Int Immunopharmacol; 2024 Jan; 126():111269. PubMed ID: 38006753
[TBL] [Abstract][Full Text] [Related]
37. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine treatment alters retinal layers and choroid without apparent toxicity in optical coherence tomography.
Polat OA; Okçu M; Yılmaz M
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102806. PubMed ID: 35288317
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Tarassoly K; Miraftabi A; Sedaghat A; Parvaresh MM
Int Ophthalmol; 2023 May; 43(5):1737-1743. PubMed ID: 36414851
[TBL] [Abstract][Full Text] [Related]
40. Quantitative assessment of outer retinal layers and ellipsoid zone mapping in hydroxychloroquine retinopathy.
Ugwuegbu O; Uchida A; Singh RP; Beven L; Hu M; Kaiser S; Srivastava SK; Ehlers JP
Br J Ophthalmol; 2019 Jan; 103(1):3-7. PubMed ID: 30190364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
